Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)

Dr. Christos Fountzilas

Oncology
Roswell Park Cancer Institute
Elm And Carlton St, 
Buffalo, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Roswell Park Cancer Institute
Elm And Carlton St, 
Buffalo, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christos Fountzilas is an Oncologist in Buffalo, New York. Dr. Fountzilas is rated as an Experienced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Pancreatic Cancer, and Stomach Cancer.

His clinical research consists of co-authoring 65 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Head and Neck Squamous Cell Carcinoma (HNSCC).

Specialties
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

ROSWELL PARK CANCER INSTITUTE
Elm And Carlton St, Buffalo, NY 14263

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Procedure, Other, Radiation
Study Drug: Peposertib
Study Phase: Phase 1/Phase 2
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: July 14, 2025
Intervention Type: Drug, Biological
Study Drugs: Fluorouracil, Irinotecan, Irinotecan hydrochloride, Leucovorin, Leucovorin calcium, Paclitaxel, Ramucirumab
Study Phase: Phase 2
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Enrollment Status: Suspended
Publish Date: October 07, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Pembrolizumab
Study Phase: Phase 2
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: September 16, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-Treated Metastatic Colorectal Cancer (TABAsCO)
A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-Treated Metastatic Colorectal Cancer (TABAsCO)
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Drug, Biological
Study Drugs: Irinotecan, Bevacizumab, Trifluridine, Tipiracil
Study Phase: Phase 2
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) High Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) High Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
Enrollment Status: Terminated
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 2
Perioperative Analysis of Binimetinib and Palbociclib in RAS-Driven Tumors
Perioperative Analysis of Binimetinib and Palbociclib in RAS-Driven Tumors
Enrollment Status: Withdrawn
Publish Date: December 22, 2023
Intervention Type: Drug, Procedure
Study Drugs: Binimetinib, Palbociclib
Study Phase: Early Phase 1
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: January 03, 2023
Intervention Type: Drug
Study Drugs: CPI 613, mFolfirinox, Folfirinox
Study Phase: Phase 3
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
A Phase IIa Study of Rintatolimod Plus Pembrolizumab in Refractory Metastatic Colorectal Cancer
A Phase IIa Study of Rintatolimod Plus Pembrolizumab in Refractory Metastatic Colorectal Cancer
Enrollment Status: Withdrawn
Publish Date: February 08, 2022
Intervention Type: Other, Drug, Biological
Study Phase: Phase 2
View 11 Less Clinical Trials

65 Total Publications

HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.
Journal: Future oncology (London, England)
Published: October 15, 2025
Similar Doctors
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Michael K. Wong
Oncology
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Michael K. Wong
Oncology

Roswell Park Cancer Institute

Elm And Carlton St, 
Buffalo, NY 
 (0.1 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances

Michael Wong is an Oncologist in Buffalo, New York. Dr. Wong is rated as an Advanced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Merkel Cell Carcinoma, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Melanoma.

Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Edwin J. Yau
Oncology
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Edwin J. Yau
Oncology

Roswell Park Cancer Institute

Elm And Carlton St, 
Buffalo, NY 
 (0.1 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances

Edwin Yau is an Oncologist in Buffalo, New York. Dr. Yau is rated as an Advanced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, EGFR Positive Lung Cancer, and Large-Cell Lung Carcinoma.

Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Rosalyn A. Juergens
Oncology
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Rosalyn A. Juergens
Oncology
Juravinski Cancer Centre, 699 Concession Street - Fourth Floor Room 228, 
Hamilton, ON, CA 
 (54.6 miles away)
905-387-9711
Languages Spoken:
English
See accepted insurances

Rosalyn Juergens is an Oncologist in Hamilton, Canada. Dr. Juergens is rated as an Advanced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Neuroendocrine Tumor, Small Cell Lung Cancer (SCLC), and Tissue Biopsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fountzilas's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile